Omnicell (NASDAQ:OMCL) Releases FY 2026 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 2.150-2.300 for the period, compared to the consensus earnings per share estimate of 1.810. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Omnicell also updated its Q3 2026 guidance to 0.350-0.430 EPS.

Analysts Set New Price Targets

A number of research analysts have issued reports on OMCL shares. KeyCorp upped their price target on shares of Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Zacks Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Craig Hallum restated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $59.86.

Omnicell Trading Down 3.8%

Shares of Omnicell stock opened at $41.40 on Thursday. The stock has a market cap of $1.88 billion, a PE ratio of 94.09, a price-to-earnings-growth ratio of 1.11 and a beta of 0.96. The firm has a fifty day moving average price of $42.29 and a 200 day moving average price of $41.23. Omnicell has a 1 year low of $28.90 and a 1 year high of $55.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.48 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities research analysts predict that Omnicell will post 1.31 earnings per share for the current year.

Insider Transactions at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the transaction, the executive vice president directly owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the sale, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by corporate insiders.

Institutional Trading of Omnicell

Hedge funds have recently added to or reduced their stakes in the company. Cerity Partners LLC boosted its holdings in Omnicell by 4.9% during the fourth quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock worth $345,000 after buying an additional 354 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in Omnicell by 1.2% in the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after buying an additional 424 shares in the last quarter. Legal & General Group Plc increased its holdings in Omnicell by 0.3% in the third quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after buying an additional 448 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Omnicell by 1.7% in the second quarter. California State Teachers Retirement System now owns 42,552 shares of the company’s stock worth $1,251,000 after acquiring an additional 692 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Omnicell during the 2nd quarter valued at approximately $26,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.